| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cancer Stem Cells |
1 Program for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts; Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota
2 Program for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts; Society of Fellows, Harvard University, Cambridge, Massachusetts
* To whom correspondence should be addressed. E-mail: dingli{at}fas.harvard.edu.
 |
Abstract |
|---|
Despite significant improvements in cancer therapy, tumor recurrence is frequent and can be due to a variety of mechanisms, including the evolution of resistance and tumor progression. Cancer stem cells have been postulated to maintain tumor growth similar to normal stem cells maintaining tissue homeostasis. Recently, the existence of these malignant stem cells has been proven for hematological as well as some solid tumors. Tumor stem cells are not targeted by standard therapy and might be responsible for treatment failure and tumor recurrence in many patients. We design a simple mathematical model to demonstrate the importance of eliminating tumor stem cells. We explore different therapeutic scenarios to illustrate the properties required from novel therapeutic agents for successful tumor treatment. We show that successful therapy must eradicate tumor stem cells.
Key Words. Hematopoiesis, cancer, stem cell, mathematical modeling, therapy
This article has been cited by other articles:
|
|
 |
|
  B. M. Boman and M. S. Wicha Cancer Stem Cells: A Step Toward the Cure J. Clin. Oncol., June 10, 2008; 26(17): 2795 - 2799. [Full Text] [PDF]
|
|
|
|
|
|
F. Michor Mathematical Models of Cancer Stem Cells J. Clin. Oncol., June 10, 2008; 26(17): 2854 - 2861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Shu, K. K. Wong, J. M. Su, A. M. Adesina, L. T. Yu, Y. T. M. Tsang, B. C. Antalffy, P. Baxter, L. Perlaky, J. Yang, et al. Direct Orthotopic Transplantation of Fresh Surgical Specimen Preserves CD133+ Tumor Cells in Clinically Relevant Mouse Models of Medulloblastoma and Glioma Stem Cells, June 1, 2008; 26(6): 1414 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Branford, J. F. Seymour, A. Grigg, C. Arthur, Z. Rudzki, K. Lynch, and T. Hughes BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria Clin. Cancer Res., December 1, 2007; 13(23): 7080 - 7085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Lopes, J. M. Pacheco, and D. Dingli Acquired hematopoietic stem-cell disorders and mammalian size Blood, December 1, 2007; 110(12): 4120 - 4122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Michor Chronic Myeloid Leukemia Blast Crisis Arises from Progenitors Stem Cells, May 1, 2007; 25(5): 1114 - 1118. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
